We are pleased to announce that IBC will coordinate with our Pharmacy Services department to facilitate Synagis^? (palivizumab) for the 2012-2013 respiratory syncytial virus (RSV) season, which is November through April in the United States. RSV is the most common cause of bronchiolitis and pneumonia among children younger than one year of age. During the RSV season, we will approve the monthly administration of Synagis^? (palivizumab) for at-risk children younger than two years of age. It is mandatory for all participating providers to obtain Synagis among children younger than one year of age. During the RSV season, we will approve the monthly administration of Synagis^? (palivizumab) through ACRO Pharmaceutical Services, an independent company. IBC will coordinate with ACRO Pharmaceutical Services to facilitate delivery of Synagis among children younger than one year of age. During the RSV season, we will approve the monthly administration of Synagis^? (palivizumab) to your office. If you have questions about the Synagis^? (palivizumab) distribution program, please contact IBC Customer Service at 1-800-ASK-BLUE. Look for more information regarding the shipment and facilitation of Synagis^? (palivizumab) in next month?s edition of Partners in Health Update.
Note: MedImmune, LLC, the makers of Synagis^? (palivizumab), has a voluntary program called RSV Connection?. However, IBC does not participate in this program. All requests for Synagis^? (palivizumab) should be sent directly to ACRO Pharmaceutical Services. Prior authorization forms can be obtained by contacting ACRO Pharmaceutical Services at 1-800-906-7798.

This is not a statement of benefits. Benefits may vary according to state requirements, product line (HMO, PPO, etc.), and/or employer groups. Member coverage can be verified by calling Customer Service at 1-800-ASK-BLUE.